SCHEMBL5041435

SCHEMBL5041435

O=C(O)Nc1ncc(CC(=O)Nc2cccc(F)c2)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.53
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
CDK2 P24941 3/20 0.50
CCNE1 P24864 2/20 0.50
CDK5 Q00535 2/20 0.50
AURKB Q96GD4 2/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
HTT P42858 1/20 0.46
MAPT P10636 2/20 0.46
TP53 P04637 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
EGFR P00533 1/20 0.44
IGF1R P08069 1/20 0.44
FGFR1 P11362 1/20 0.44
SRC P12931 1/20 0.44
FGFR2 P21802 1/20 0.44
FGFR4 P22455 1/20 0.44
FGFR3 P22607 1/20 0.44
KDR P35968 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12523205 0.87 AURKA (0.51) AURKAKMT2AMEN1CDK2CCNE1
SCHEMBL5027736 0.85 AURKA (0.49) AURKAKMT2AMEN1CDK2CCNE1
SCHEMBL5045023 0.84 AURKA (0.52) AURKAKMT2AMEN1CDK2CCNE1
SCHEMBL707268 0.83 KMT2A (0.55) AURKAKMT2AMEN1AURKBSMN1; SMN2
SCHEMBL12455691 0.83 AURKA (0.51) AURKAKMT2AMEN1CDK2CCNE1
SCHEMBL12455785 0.82 AURKA (0.55) AURKAKMT2AMEN1CDK2CCNE1
SCHEMBL27637763 0.79 AURKA (0.50) AURKAKMT2AMEN1CDK2CCNE1
SCHEMBL12455712 0.79 AURKA (0.50) AURKAKMT2AMEN1CDK2CCNE1
SCHEMBL12455701 0.79 AURKA (0.50) AURKAKMT2AMEN1CDK2CCNE1
SCHEMBL12455699 0.78 AURKA (0.49) AURKAKMT2AMEN1CDK2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407946-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2008-08-05 US disclosed
US-20060058523-A1 Quinazoline compounds ASTRAZENECA AB (SE) 2006-03-16 US disclosed
EP-1575946-A1 QUINAZOLINE COMPOUNDS AstraZeneca AB (SE) 2005-09-21 EP disclosed
WO-2004058752-A1 QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058523-A1 Quinazoline compounds NDUFS5, ABL1, NDUFS7 AURKA 509/4885KMT2A 2083/4885MEN1 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.